ÂÜÀòÂÒÂ×

Dr. Leyland-Jones is the Chief Medical Officer and Scientific Advisory Board Member for the National Foundation for Cancer Research (NFCR). He also serves as the Chief Medical Officer of OTraces, SCITech Development, and the N OF 1 Mission. Dr. Leyland-Jones is also the CSO of The Darwin Foundation, collectively devoted to the implementation of prevention and cure of malignancy globally. He sits on several national and international boards including the Asian Foundation for Cancer Research (AFCR), NED Biosystems, Non-Pareil, and Ratio. He is the Director Emeritus for the WIN Consortium. He founded several companies, including Xanthus, AKESOgen, and Viviphi. Dr. Leyland-Jones holds biochemistry, medical, and doctoral degrees from the University of London. Following residency training at Hammersmith, Brompton, St. Bartholomew’s, and London hospitals, he completed a clinical pharmacology fellowship at Cornell University and a medical oncology fellowship at Memorial Sloan-Kettering Cancer Center. He then joined the academic staff at Memorial Sloan-Kettering Cancer Center and New York Hospitals with a special research interest in Early Phase clinical, clinical pharmacological, and biomarker evaluation of many anticancer compounds, including the platinum and anthracycline analogs in use today. In 1983, he moved to the National Cancer Institute (NCI) to head the Developmental Chemotherapy section. During his time with the NCI, he was responsible for the overall development of approximately 70 anti-cancer compounds in various stages of transition from in-vitro screening to Phase III clinical trials.